Orchard To Use Divested GSK Rare Disease Gene Therapies To Grow Globally

Orchard Therapeutics will acquire GSK’s portfolio of approved and investigational rare disease gene therapies, including EU-approved Strimvelis and additional late-stage gene therapies.

DNA
GSK Taking 19.9% Stake In Orchard As Part Of Transfer Deal • Source: Shutterstock

Orchard Therapeutics says it will benefit hugely from GlaxoSmithKline PLC's decision to sell its rare disease portfolio to the three-year old UK biotech, and that its gene therapy programs will remain unencumbered by the 19.9% equity stake and board position that GSK will receive in return.

Britain's biggest drug maker said on April 12 that it would transfer its rare disease gene therapy drugs to privately...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.